123 related articles for article (PubMed ID: 32535330)
21. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
23. Indole derivatives as multifunctional drugs: Synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity of indole hydrazones.
Demurtas M; Baldisserotto A; Lampronti I; Moi D; Balboni G; Pacifico S; Vertuani S; Manfredini S; Onnis V
Bioorg Chem; 2019 Apr; 85():568-576. PubMed ID: 30825715
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents.
Alam MS; Lee DU
Arch Pharm Res; 2016 Feb; 39(2):191-201. PubMed ID: 26694484
[TBL] [Abstract][Full Text] [Related]
26. Ligand-based autotaxin pharmacophore models reflect structure-based docking results.
Mize CD; Abbott AM; Gacasan SB; Parrill AL; Baker DL
J Mol Graph Model; 2011 Nov; 31():76-86. PubMed ID: 21967734
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.
Lei H; Wang X; Zhao G; Li T; Cui Y; Wu H; Yang J; Jiang N; Zhai X
Eur J Med Chem; 2022 Jun; 236():114307. PubMed ID: 35436669
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors.
Alam MS; Choi SU; Lee DU
Bioorg Med Chem; 2017 Jan; 25(1):389-396. PubMed ID: 27856237
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
[TBL] [Abstract][Full Text] [Related]
30. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
Vlasceanu A; Jessing M; Kilburn JP
Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis, and Cytotoxicity of Novel 2,4,6-Trisubstituted 1,3,5- triazines Bearing Aryl Hydrazone Moiety as Potent Antitumor Agent.
Wang L; Zhao S; Bao G; Zhang Y; Xi S; Zhou G; Zhai X; Gong P
Med Chem; 2016; 12(7):621-630. PubMed ID: 26732116
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.
Ma J; Bao G; Wang L; Li W; Xu B; Du B; Lv J; Zhai X; Gong P
Eur J Med Chem; 2015; 96():173-86. PubMed ID: 25874341
[TBL] [Abstract][Full Text] [Related]
33. Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids.
Eymery MC; Nguyen KA; Basu S; Hausmann J; Tran-Nguyen VK; Seidel HP; Gutierrez L; Boumendjel A; McCarthy AA
Eur J Med Chem; 2024 Jan; 263():115944. PubMed ID: 37976710
[TBL] [Abstract][Full Text] [Related]
34. Aminoadamantanes containing monoterpene-derived fragments as potent tyrosyl-DNA phosphodiesterase 1 inhibitors.
Ponomarev KY; Suslov EV; Zakharenko AL; Zakharova OD; Rogachev AD; Korchagina DV; Zafar A; Reynisson J; Nefedov AA; Volcho KP; Salakhutdinov NF; Lavrik OI
Bioorg Chem; 2018 Feb; 76():392-399. PubMed ID: 29248742
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Structure-Activity Relationship; Exploration of some Potent Anti-Cancer Phenyl Amidrazone Derivatives.
Habashneh AY; El-Abadelah MM; Bardaweel SK; Taha MO
Med Chem; 2018; 14(5):468-477. PubMed ID: 29205121
[TBL] [Abstract][Full Text] [Related]
38. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
39. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
40. Analogue-based design, synthesis and biological evaluation of 3-substituted-(methylenehydrazono)indolin-2-ones as anticancer agents.
Dweedar HE; Mahrous H; Ibrahim HS; Abdel-Aziz HA
Eur J Med Chem; 2014 May; 78():275-80. PubMed ID: 24686014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
